Opportunities and challenges of mRNA technologies in development of Dengue Virus Vaccine

TL;DR

This paper reviews recent progress and challenges in developing mRNA-based dengue vaccines, highlighting their potential to overcome limitations of current vaccines and improve global dengue prevention.

Contribution

It provides a comprehensive overview of recent clinical trial data and innovations in mRNA vaccine development for dengue, emphasizing new strategies to address existing vaccine limitations.

Findings

mRNA vaccines show promise in dengue prevention

Current vaccines face challenges like ADE

Innovative strategies may improve vaccine efficacy

Abstract

Dengue virus (DENV) is a mosquito-borne virus with a significant human health concern. With 390 million infections annually and 96 million showing clinical symptoms, severe dengue can lead to life-threatening conditions like dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The only FDA-approved vaccine, Dengvaxia, has limitations due to antibody-dependent enhancement (ADE), necessitating careful administration. The recent pre-approval of TAK-003 by WHO in 2024 highlights ongoing efforts to improve vaccine options. This review explores recent advancements in dengue vaccine development, emphasizing potential utility of mRNA-based vaccines. By examining current clinical trial data and innovations, we aim to identify promising strategies to address the limitations of existing vaccines and enhance global dengue prevention efforts.